BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 3198217)

  • 1. Determination of cisplatin in blood compartments of cancer patients.
    Mustonen R; Hemminki K; Alhonen A; Hietanen P; Kiilunen M
    IARC Sci Publ; 1988; (89):329-32. PubMed ID: 3198217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction and removal of cisplatin-DNA adducts in human cells in vivo and in vitro as measured by immunochemical techniques.
    Fichtinger-Schepman AM; Dijt FJ; Bedford P; van Oosterom AT; Hill BT; Berends F
    IARC Sci Publ; 1988; (89):321-8. PubMed ID: 3198216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA adducts of cisplatin and carboplatin in tissues of cancer patients.
    Poirier MC; Egorin MJ; Fichtinger-Schepman AM; Yuspa SH; Reed E
    IARC Sci Publ; 1988; (89):313-20. PubMed ID: 3058599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival.
    Fisch MJ; Howard KL; Einhorn LH; Sledge GW
    Clin Cancer Res; 1996 Jun; 2(6):1063-6. PubMed ID: 9816268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation.
    Gupta-Burt S; Shamkhani H; Reed E; Tarone RE; Allegra CJ; Pai LH; Poirier MC
    Cancer Epidemiol Biomarkers Prev; 1993; 2(3):229-34. PubMed ID: 8318875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.
    Reed E; Yuspa SH; Zwelling LA; Ozols RF; Poirier MC
    J Clin Invest; 1986 Feb; 77(2):545-50. PubMed ID: 3944268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of carcinogen-DNA adducts by immunoassay.
    Poirier MC; Liou SH; Reed E; Strickland PT; Tockman MS
    J UOEH; 1989 Mar; 11 Suppl():353-67. PubMed ID: 2664949
    [No Abstract]   [Full Text] [Related]  

  • 10. Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy.
    Poirier MC; Reed E; Shamkhani H; Tarone RE; Gupta-Burt S
    Environ Health Perspect; 1993 Mar; 99():149-54. PubMed ID: 8319613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.
    Reed E; Parker RJ; Gill I; Bicher A; Dabholkar M; Vionnet JA; Bostick-Bruton F; Tarone R; Muggia FM
    Cancer Res; 1993 Aug; 53(16):3694-9. PubMed ID: 8339278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA.
    Meczes EL; Azim-Araghi A; Ottley CJ; Pearson DG; Tilby MJ
    Biochem Pharmacol; 2005 Dec; 70(12):1717-25. PubMed ID: 16259963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
    Veal GJ; Dias C; Price L; Parry A; Errington J; Hale J; Pearson AD; Boddy AV; Newell DR; Tilby MJ
    Clin Cancer Res; 2001 Aug; 7(8):2205-12. PubMed ID: 11489793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomonitoring of cisplatin-DNA adducts in cancer patients receiving cisplatin chemotherapy.
    Reed E; Ozols RF; Fasy T; Yuspa SH; Poirier MC
    Prog Clin Biol Res; 1986; 209B():247-52. PubMed ID: 3749082
    [No Abstract]   [Full Text] [Related]  

  • 15. Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation.
    Evans DL; Tilby M; Dive C
    Cancer Res; 1994 Mar; 54(6):1596-603. PubMed ID: 8137265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II).
    Fichtinger-Schepman AM; van Oosterom AT; Lohman PH; Berends F
    Cancer Res; 1987 Jun; 47(11):3000-4. PubMed ID: 3552211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
    Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):329-36. PubMed ID: 14673619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High performance liquid chromatographic determination of platinum in blood and urine samples of cancer patients after administration of cisplatin drug using solvent extraction and N,N'-bis(salicylidene)-1,2-propanediamine as complexation reagent.
    Lanjwani SN; Zhu R; Khuhawar MY; Ding Z
    J Pharm Biomed Anal; 2006 Mar; 40(4):833-9. PubMed ID: 16181764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation of platinum-DNA adducts in pediatric patients receiving carboplatin.
    Tonda ME; Murry DJ; Rodman JH
    Pharmacotherapy; 1996; 16(4):631-7. PubMed ID: 8840369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.
    Welters MJ; Fichtinger-Schepman AM; Baan RA; Jacobs-Bergmans AJ; Kegel A; van der Vijgh WJ; Braakhuis BJ
    Br J Cancer; 1999 Jan; 79(1):82-8. PubMed ID: 10408697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.